UPDATE: Morgan Stanley Initiates Pfizer With Overweight, $48 Target As Firm Notes Co's 'organic growth is set to accelerate next year after two decades of challenges, driven by fading patent expiration pressures and contributions from new revenue drivers'
Benzinga_Newsdesk